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EDITORIAL 
What’s the Excitement about Excitatory 
Armno Acids in Amyotrophic Lateral 
Sclerosis? 
In this issue, one review and two original articles ap- 
pear that address the potential role of excitatory amino 
acids in the pathogenesis of amyotrophic lateral sclero- 
sis (ALS) 11-31. The hypothesis, as put forward by 
Plaitakis 1 11, is that a generalized defect in excitatory 
amino acid metabolism in ALS may render select 
groups of neurons vulnerable to excitatory amino 
acid-induced neurotoxic damage because of their 
unique neuronal properties and the neurochemical 
character of their connections. Several studies are cited 
as providing evidence for increased plasma and cere- 
brospinal fluid (CSF) glutamate concentrations in pa- 
tients with ALS, and also decreased concentrations of 
brain glutamate and decreased spinal cord glutamate, 
aspartate, N-acetylaspartate (NAA), and N-acetyl- 
aspartyl glutamate (NAAG). Plaitakis concludes that 
the data support the notion of a generalized defect in 
glutamate metabolism in ALS rather than a selective 
defect in nezlronal glutamate transport, metabolism, 
storage, release, or receptors. Why, then, is ALS char- 
acterized by such regionally specific pathological find- 
ings? Would not other regions of the nervous system 
be affected in ALS if glutamate (which is a neuro- 
transmitter and a potential neurotoxin throughout 
brain) is metabolized abnormally? Plaitakis argues that 
the selective vulnerability may reside in the particular 
properties of motor neuron innervation or factors that 
could abnormally potentiate this innervation, or both. 
H e  suggests that one such potentiator could be gly- 
cine. Glycine is an inhibitory neurotransmitter of inter- 
neurons in spinal cord and brainstem and is uniquely 
present in high concentrations in these regions. It is 
also a positive modulator of one subtype of glutamate 
receptor, the N-methyl-D-aspartate (NMDA) recep- 
tor. The NMDA receptor is thought to play a crucial 
role in glutamate-induced neurotoxicity 143. Glycine 
enhances glutamate’s excitatory actions at the NMDA 
receptor and promotes recovery of NMDA receptors 
after glutamate-induced desensitization. Thus, many 
nervous system regions may be able to compensate for 
high extracellular glutamate concentrations except in 
spinal cord and brainstem where glycine enhances 
glutamate’s actions. In support of Plaitakis’ hypothesis 
is the observation that persons develop selective upper 
and lower motor neuron disorders after exposure to 
the glutamatergic neurotoxins in Lathyrzls sutizu and 
Cycus circinalir 151. 
The data of Rothstein and coworkers 131 support 
Plaitakis’ hypothesis by demonstrating 100 to 2009% 
increases in glutamate and aspartate concentrations in 
CSF of patients with ALS. CSF NAA and NAAG are 
also shown to be increased several-fold. In spinal cord 
of patients with ALS, NAA and NAAG concentra- 
tions are reportedly decreased. In contrast, Perry’s 
group 121 found no abnormahties in CSF glutamate 
and aspartate levels in patients with ALS. Additionally, 
they found increases in plasma glutamate in patients 
with ALS, as observed previously by others, but they 
attributed these changes to age differences between 
the ALS and control groups. 
What factors can account for the differences be- 
tween these two studies? The patients studied by 
Rothstein and associates had been symptomatic for 
half as long as those in Perry and colleagues’ study. 
Perhaps in more advanced disease, CSF glutamate 
levels decrease because of the decreased tissue levels 
of glutamate. Perry and colleagues’ patients, however, 
did not show a trend toward decreased CSF gluta- 
mate concentrations with more advanced disease, and 
Rothstein and associates’ data did not suggest a pro- 
gressive decrease in tissue glutamate levels with ad- 
vancing disease. Rothstein and colleagues included 
only patients with both upper and lower motor neuron 
disease, whereas Perry and coworkers also included 
those with only lower motor neuron disease. There is 
some evidence that isolated lower motor neuron dis- 
ease may have a different origin than ALS 161. 
The striking discrepancy, however, between the 
Rothstein and the Perry studies is the tremendous dif- 
ference in total glutamate and aspartate concentrations 
measured in CSF. In controls, Rothstein and cowork- 
ers report glutamate concentrations of 2.9 FmoVL, 
whereas Perry’s group reports glutamate concentra- 
tions of 0.2 FmoYL. These values represent a 15-fold 
difference in concentration. Even greater differences 
are observed in aspartate concentrations. Except for 
glycine and cystine, other amino acid concentrations 
are similar in the two studies. Perry and associates ex- 
plain that glutamate concentrations must be measured 
in CSF that is deproteinized immediately. Otherwise, 
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enzymes in CSF will metabolize the amino acids and 
artificially elevate glutamate and aspartate levels and 
lower glutamine and asparagine levels. In 1975, Perry’s 
group revised their estimates of normal CSF amino 
acid levels based on analysis of deproteinized fluid. At 
that time, they reported the CSF glutamate values for 
normal adults as 1.8 pmol/L {7]. In the current paper 
by Perry and coworkers, they find normal values one- 
tenth the earlier revised values using seemingly identi- 
cal methodology. In fact, the Perry group’s current 
values appear to be below the sensitivity of the assay 
for aspartate and to approach the sensitivity of the 
assay for glutamate, since only one significant digit is 
provided and the standard deviations are large. Is it 
possible that a more sensitive assay might show differ- 
ences between control and ALS CSF glutamate con- 
centrations? The Perry group’s low CSF glutamate and 
aspartate values “make sense” to the extent that the 
nervous system would be expected to have low CSF 
concentrations of excitatory amino acids so that normal 
neurotransmission would not be disrupted. Further- 
more, Perry and colleagues have used the same assay 
to show that CSF glutamate concentrations are higher 
in patients with Huntington’s disease than in control 
patients [g]. Which CSF values are correct, those of 
Rothstein’s group or those of Perry’s group? Could the 
sulfasalicylic acid used by Perry’s group precipitate 
glutamate and aspartate with the protein? What hap- 
pens to exogenously added glutamate in this assay? 
Rothstein and colleagues did not deproteinite their 
fluid, but they assayed the CSF of the controls in paral- 
lel with that of the ALS patients and found differences. 
What factors influenced the observed difference be- 
tween the ALS patients and the controls? Do the CSF 
enzymes in ALS metabolize amino acids differently 
than they do in controls? Further experimentation will 
be necessary to clarify these issues. 
Perry and associates’ conclusion that plasma gluta- 
mate concentrations are not different between ALS pa- 
tients and controls seems a bit unwarranted given their 
current and prior data. Although the control plasma 
glutamate concentrations in this study showed a corre- 
lation with advancing age, in a previous study of twice 
as many controls, these investigators found no correla- 
tion in plasma glutamate concentrations with age [S]. It 
would seem more appropriate to reassess this issue 
using an age-matched control group prior to conclud- 
ing that glutamate does not play a role in this disease. 
This is especially true because Perry’s group has dem- 
onstrated previously widespread decreases in brain 
glutamate in ALS E91. 
It appears that although the hypothesis is intriguing, 
considerably more information needs to be gathered 
prior to concluding that excitatory amino acids play a 
role in ALS. In addition, more attention needs to be 
paid to the selective vulnerability issues raised by 
Plaitakis. For instance, the hypothesis that glycine acts 
in specific regions as a potentiator of glutamate’s ac- 
tions is very interesting. Based on the hypothesis, how- 
ever, one would expect to see pathological findings in 
the third nerve nuclei, the periaqueductal gray, and 
other brainstem structures usually not affected in ALS 
[lo]. Likewise, glycine interneurons are not present in 
motor cortex where pathological findings are promi- 
nent. Furthermore, CSF and tissue glycine levels are 
thought to be high enough to saturate physiologically 
the glycine modulatory site on the NMDA receptor in 
most regions of brain [l l] .  Finally, spinal cord and 
brainstem have very low densities of NMDA recep- 
tors (about a twentieth those observed in hippocam- 
pus). These discrepancies deserve further considera- 
tion. If a generalized defect in glutamate metabolism 
does exist in ALS, perhaps it is a proximate cause of 
selective neuronal vulnerability but nor the primary 
one. If certain groups of nerve cells are not healthy for 
other reasons, they may become differentially suscepti- 
ble to excitatory amino acid-induced damage [12). 
One potential approach to the issues might be a study 
of offspring of persons with familial ALS. Glutamate 
metabolism could be measured prospectively and cor- 
related with the onset of symptoms. 
Although the hypothesis that excitatory amino acids 
play a role in the pathogenesis of ALS remains specula- 
tive, this idea is exciting because of its therapeutic im- 
plications. Plaitakis has carried out a trial of branched 
chain amino acids in ALS based on the theory that 
these amino acids might stimulate glutamate metabo- 
lism and thereby decrease brain glutamate levels [13]. 
A larger study using these amino acids is now in prog- 
ress (M. B. Bromberg, personal communication). An- 
tagonists of NMDA receptors are now available and 
dextromethorphan, which blocks NMDA receptor- 
associated ion channels {4],  is being examined thera- 
peutically in ALS (R. Roos, E. Salazar-Grueso, per- 
sonal communication, 1990). ALS is a tragic disease 
and it would be a real breakthrough if such therapies 
proved effective. Nevertheless, clinical trials of pre- 
ventive therapies are very expensive and labor inten- 
sive. Premature initiation of large trials without con- 
vincing preliminary data would be a mistake. 
Anne B. Young, MD, PhD 
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